Deltec Asset Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Deltec Asset Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,000	Closed	-$53K	–	321
2021 Q2	$53K	Hold	10,000	–	–	0.01%	291
2021 Q1	$48K	Sell	10,000 -235,399	-96%	-$1.23M	0.01%	289
2020 Q4	$1.06M	Sell	245,399 -110,446	-31%	-$473K	0.16%	102
2020 Q3	$1.47M	Hold	355,845	–	–	0.26%	79
2020 Q2	$911K	Sell	355,845 -46,000	-11%	-$135K	0.19%	116
2020 Q1	$1.16M	Buy	401,845 +3,236	+0.8%	+$14.5K	0.32%	56
2019 Q4	$1.51M	Sell	398,609 -176,277	-31%	-$844K	0.31%	60
2019 Q3	$2.94M	Buy	574,886 +24,050	+4%	+$148K	0.74%	40
2019 Q2	$3.42M	Buy	550,836 +14,000	+3%	+$80.5K	0.75%	36
2019 Q1	$3.82M	Buy	536,836 +300,712	+127%	+$2.7M	0.83%	31
2018 Q4	$2.02M	Sell	236,124 -143,300	-38%	-$1.86M	0.56%	45
2018 Q3	$7.6M	Buy	379,424 +19,628	+5%	+$461K	1.46%	20
2018 Q2	$9.29M	Buy	359,796 +139,500	+63%	+$3.86M	1.88%	15
2018 Q1	$5.26M	Buy	220,296 +119,996	+120%	+$3.78M	1.05%	30
2017 Q4	$3.4M	Buy	+100,300	New	+$2.8M	0.69%	47

Other funds holding ADMS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CCPM

Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deltec Asset Management's ADMS Position: Q3 2021 in Review

Deltec Asset Management sold out of Adamas Pharmaceuticals (ADMS) in Q3 2021, closing a stake of 10,000 shares — an estimated $53K sold.

Deltec Asset Management first reported a position in ADMS in Q4 2017 and held it in 15 quarters. The position peaked at $9.29M in Q2 2018. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2021.

Deltec Asset Management reported no remaining Adamas Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Deltec Asset Management sold 10,000 Adamas Pharmaceuticals shares in Q3 2021, an estimated $53K.
Deltec Asset Management first reported a position in Adamas Pharmaceuticals in Q4 2017 and held it in 15 quarters.
Deltec Asset Management's Adamas Pharmaceuticals position peaked at $9.29M in Q2 2018.
63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2021.

Based on Deltec Asset Management's 13F filing for Q3 2021, filed 13 Oct 2021.